FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

Erratum to: Cancer Immunol Immunother DOI 10.1007/s00262-008-0613-3

It has been brought to author’s attention that Fig. 2 contains major error. Specifically, in Fig. 2a, the ‘F/V’ and the ‘V/V’ figures are identical. The correct version is given below:

Fig. 2

NK FcγRIIIa polymorphisms influencing cytotoxic activity on cetuximab-treated SCCHN TU167. a NK cells from individual donors expressing either F/F, V/F or V/V alleles were tested for cytotoxicity against TU167 in a standard ⁵¹Cr-release assay. Before addition of effector cells, TU167 target cells were pretreated with media alone (filled diamond), human IgG1 isotype control at 10 μg/ml (filled square) or cetuximab 10 μg/ml (filled triangle). Data are representative of independent experiments performed in triplicates, with error bars indicating SEM. b NK cells from 17 donors expressing either F/F, V/F or V/V alleles were tested for cytotoxicity against the TU167 SCCHN cell line using a standard ⁵¹Cr-release assay. Before addition of effector cells TU167 targets were pretreated with media alone, human IgG1 isotype control at 10 μg/ml, or cetuximab at 10 μg/ml. Donors with either FcγRIIIa V/V or FcγRIIIa V/F demonstrated significantly higher % cytotoxicity compared to FcγRIIIa F/F, when incubated with 10 μg/mL cetuximab (P = 0.04 and 0.004, respectively). Shown is the mean of n = 7, 7 and 3 for FF, VF and VV, respectively, with error bars representing SEM